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INTRODUCTION
Extracellular adenosine, by activating cell-surface, G-protein-coupled adenosine receptors, exerts wide-ranging effects on many organ systems (Fredholm, 2010; Fredholm et al., 2011) . For example, the receptor-mediated effects of extracellular adenosine influence numerous physiological variables including heart rhythm (Shryock and Belardinelli, 1997), neurotransmission [both in the central nervous system (CNS) (Boison, 2007; Sperlagh and Vizi, 2011) and peripheral nervous system (PNS) (Shepherd and Vanhoutte, 1985; Richardt et al., 1996) ], vascular tone (Headrick et al., 2013) , cell survival post-injury (Forman et al., 2006) and immune system responses (Sitkovsky et al., 2004; Eltzschig, 2009; Ohta and Sitkovsky, 2009; Linden, 2011) . These effects of adenosine suggest opportunities to develop drugs that affect organ systems by influencing extracellular adenosine levels or adenosine receptor activation.
Thus it is important to understand the mechanisms controlling extracellular adenosine levels within specific cellular environments.
An important determinant of extracellular adenosine levels is the rate of adenosine production in the extracellular compartment. In this regard, the classical pathway mediating extracellular adenosine formation is the conversion of extracellular ATP to adenosine (via the sequential actions of the ecto-enzymes CD39 and CD73) (Eltzschig and Carmeliet, 2011; Eltzschig et al., 2012; Eltzschig, 2013) . However, accumulating evidence suggests that in addition to extracellular ATP, extracellular cAMPs also can be converted to adenosine.
Specifically, studies show that both extracellular 3',5'-cAMP (Jackson and Raghvendra, 2004) and extracellular 2',3'-cAMP (Jackson, 2011) [positional isomer of 3',5'-cAMP recently discovered to exist in intact organs and in vivo Ren et al., 2009; Verrier et al., 2012) ] can serve as a source of extracellular adenosine production. Hormonal activation of adenylyl cyclases results in intracellular production of 3',5'-cAMP, which is actively transported to the extracellular compartment and there metabolized to 5'-AMP and then to adenosine (i.e., the extracellular 3',5'-cAMP-adenosine pathway) (Jackson and Raghvendra, 2004) . Cellular 
JPET #225219
5 injury/energy depletion triggers the breakdown of RNA by RNases producing intracellular 2',3'-cAMP that is transported to the extracellular compartment and there converted to 2'-AMP and 3'-AMP which in turn are metabolized to adenosine (i.e., the extracellular 2',3'-cAMP-adenosine pathway) (Jackson, 2011) .
Our recent studies demonstrate that of the two extracellular cAMP-adenosine pathways, the extracellular 2',3'-cAMP-adenosine pathway is more active in the brain than the extracellular 3',5'-cAMP-adenosine pathway. In this regard, the brain converts extracellular 2',3'-cAMP to 2'-AMP and 3'-AMP and metabolizes extracellular 2'-AMP and 3'-AMP to adenosine (Verrier et al., 2012) . Recent studies suggest that in the brain the conversion of extracellular 2',3'-cAMP to 2'-AMP is mediated mostly by 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase) (Verrier et al., 2012; Verrier et al., 2013 ). This conclusion is based on the observations that in CNPase knockout mice the conversion of exogenous 2',3'-cAMP to 2'-AMP is impaired and traumatic brain injury increases extracellular 2'-AMP and adenosine much less in CNPase knockout mice compared with wildtype mice (Verrier et al., 2012) . Likely the abundance of oligodendrocytes in the brain is the reason that CNPase is critical to the CNS extracellular 2',3'-cAMP-adenosine pathway. This concept is based on the facts that oligodendrocytes express large amounts of CNPase (this protein is the third most abundant protein in the myelin sheath) and oligodendrocytes isolated from CNPase knockout mice generate less 2'-AMP and adenosine from 2',3'-cAMP (Verrier et al., 2013) .
Although oligodendrocytes are the myelinating glia cells in the CNS, in the PNS Schwann cells are the myelinating glia and provide both trophic and structural support to axons of the peripheral nerves (Jessen and Mirsky, 2005) . During development the pre-myelinating Schwann cells form a one-to-one relationship with axons and undergo elaborate morphological changes. The process of myelination requires vast increases in the amount of both lipid membrane and myelin specific proteins necessary to support the mature myelin. These
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MATERIALS and METHODS
Cell Culture: Primary rat Schwann cells were isolated as previously described (Verrier et al., 2009) . In brief, post-natal day 2 rat pups were anesthetized and the sciatic nerves were removed and placed in ice cold Hank's balanced salt solution (HBSS). The nerves were then dissociated with trypsin and collagenase for 15 minutes at 37ºC with occasional shaking. The protease treatment was repeated 2 more times, and then Dulbecco's modified Eagle's medium (DMEM, Life Technologies, Carlsbad, CA) with 10% fetal calf serum (FCS, Fisher Scientific, Waltham, MA) was added to quench the trypsin. The protease-treated nerve preparation was then passed through an 18-gauge needle several times, and then a 23-gauge needle until the solution was homogenous. The cells were passed through a 40-micron cell filter device, pelleted via centrifugation and then were grown in 10% FCS/DMEM containing 10 µmol/L cytosine β -D-arabinofuranoside hydrochloride (Sigma-Aldrich, St. Louis, MO) for 4 days to remove fibroblast contamination. Cells were then treated with trypsin, split 1:4 and further cultured in Schwann cell media (10% FCS in DMEM, 100 U/mL of penicillin, 100 μ g/mL of streptomycin, 2 µmol/L of forskolin, 10 µg/ml of glial growth factor) on poly-d-lysine coated plates. To induce Schwann cell differentiation, we used a previously characterized "defined" media [DMEM-F12, 100 U/mL of penicillin, 100 μ g/mL of streptomycin, 100 μ g/mL of bovine serum albumin, N2 supplement (Life Technologies), 38 ng/mL of dexamethasone, 50 ng/mL of thyroxine and 50 ng/mL of tri-iodothyronine] for 72 hours (Cheng and Mudge, 1996) .
Immunofluorescence: Primary Schwann cells grown on poly-d-lysine coated 8-well glass culture slides were used for immunofluorescence experiments to confirm the purity of our Schwann cell cultures. Approximately 25,000 primary Schwann cells were seeded into each well and allowed to proliferate for 2 days. The cells were washed twice with phosphate buffered saline (PBS) and then incubated in 4% paraformaldehyde for 15 minutes, washed again 3 times and then incubated in 100% methanol at -30ºC for 5 minutes. Cells were washed again and blocked for 1 hour with 5% goat serum in PBS. Primary antibodies were incubated overnight at We use the Schwann cell markers S100 (Millipore, Billerica, MA; antibody MAB079-1 used at 1:1000 dilution) and CNPase (Abcam, Cambridge, England; antibody ab6319 used at 1:500 dilution) to demonstrate purity of the cultures. Fluorochrome conjugated secondary antibodies (Life Technologies, used at 1:500 dilution) were used to visualize the specific staining and 4',6-diamidino-2-phenylindole (DAPI) was used for nucleus detection.
Western Blot: To detect the levels of proteins expressed in Schwann cells cultured in normal growth media compared to the defined media, western blot analysis was performed as previously described (Verrier et al., 2009 ). In brief, three separate 10-cm plates of cells per media (growth and defined) were harvested in radiological immunoprecipitation assay (RIPA) buffer containing phosphatase and protease inhibitors. Proteins were then subjected to polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane.
After blocking in 5% milk/tris buffered saline (TBS) with 0.05% Tween-20 (TBS-T), the blots were incubated with either rabbit anti-tissue non-specific alkaline phosphatase (TNAP, Novus Biologicals, Littleton, CO; antibody NBP1-95392 used at 1:5000 dilution), mouse anti-CNPase (Abcam, antibody ab6319 used at 1:500 dilution) or rabbit anti-alpha tubulin (Cell Signaling, Danvers, MA; antibody 21445 used at 1:1000 dilution) overnight. The blots were then washed three times in TBS and the appropriate horseradish peroxidase conjugated secondary antibody (Life Technologies, used at 1:10,000 dilution) was applied in 5% milk/TBS-T for 2 hours, and then the blots were incubated with chemiluminescent substrate and exposed to film.
Ex Vivo Sciatic Nerve Study: To detect endogenous cAMPs, AMPs and adenosine production from transected nerves, both sciatic nerves were isolated from four 6-week old rats and used ex vivo (Barrientos et al., 2011) . The nerves were kept in cold HBSS, cleaned of any residual muscle or connective tissues and then cut into 3 mm sections with a sterile razor. The nerve sections were then transferred to 24-well plates (2 nerve pieces per well) containing DMEM, and incubated at 37ºC for the times indicated. At the indicated time points the medium was harvested and incubated at 100ºC for 2 minutes (to denature any enzymes present in the 
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9 medium) and stored at -80ºC for later purine analysis. The nerve sections were immediately frozen, crushed under liquid nitrogen and then processed for purine analysis by extracting purines with ice-cold 1-propanol.
Metabolism Studies:
To examine purine metabolism, experiments were performed as previously described (Verrier et al., 2011) . In brief, 100,000 primary rat Schwann cells per well of a 24-well plate were grown in defined medium for 48 hours and then washed twice with 2-[4- broad spectrum phosphodiesterase inhibitor (Beavo and Reifsnyder, 1990) (CD73) inhibitor (Zimmermann, 1992) ]. After a 60-minute incubation at 37ºC, the medium was collected and immediately incubated in 100°C water bath for 2 minutes to denature enzymes. Samples were then stored at −80ºC until assayed by mass spectrometry. Total protein content of a least six wells per 24-well plate was measured using the Thermo Scientific Pierce BCA Protein Assay Kit (ThermoFisher Scientific, Waltham, MA).
Effects of DPSPX on CNPase Activity:
To investigate whether DPSPX is a CNPase inhibitor, we used purified recombinant human CNPase (OriGene, item number TP307038, Rockville, MD) and measured the conversion of 2',3'-cAMP to 2'-cAMP in the absence and presence of DPSPX. Twenty-five ng of CNPase enzyme and 30 µmol/L of 2',3'-cAMP were used per reaction. The concentrations of DPSPX were 1 mmol/L and 10 mmol/L, based on previous studies (Verrier et al. 2012) . CNPase, 2',3'-cAMP and DPSPX (where indicated) were combined in 1.5 mL centrifuge tubes and incubated at 37°C for 30 minutes. Then the tubes were placed in a 100°C water bath for 2 minutes to denature the enzyme and stop the reaction. 
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The samples were immediately placed in -80°C freezer until they were processed for measurement of 2'-AMP by mass spectrometry (see below).
Analytical Methods: Purines were measured using a modification of our previously published method . Samples were spiked with a heavy-isotope internal standard ( 13 C 10 labeled adenosine; Medical Isotopes; Pelham, NH), and purines were resolved by reversed-phase liquid chromatography (Waters UPLC BEH C18 column, 1.7 μm beads; 2.1 x 150 mm; Milford, MA) and quantified using a triple quadrupole mass spectrometer (TSQ Quantum-Ultra; ThermoFisher Scientific, San Jose, CA) operating in the selected reaction monitoring mode with a heated electrospray ionization source. The mobile phase was delivered with a Waters Acquity ultra performance liquid chromatographic system and consisted of linear gradient changes involving two buffers: Buffer A, 1% acetic acid in water; Buffer B, methanol.
The mobile phase flow rate was 300 uL/min. The gradient (A/B) was: from 0 to 2 minutes, 99.6%/0.4%; from 2 to 3 minutes, to 98.0%/2.0%; from 3 to 4 minutes, to 85.0%/15.0%; from 4 to 6.5 minutes; to 99.6%/0.4%. Instrument settings were: sample tray temperature, 10°C; column temperature, 50°C; ion spray voltage, 4.0 kilovolts; ion transfer tube temperature, 350°C; source vaporization temperature, 320°C; Q2 CID gas, argon at 1.5 mTorr; sheath gas, nitrogen at 60 psi; auxillary gas, nitrogen at 35 psi; Q1/Q3 width: 0.7/0.7 units full-width halfmaximum; scan width, 0.6 units; scan time, 0.01seconds. The m/z for the parent ions and daughter ions, the collision energy and retention time of measured purines are shown in Table   1 . The limit of detection for purines in this assay system is estimated to be 0.2 nmol/L. 
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RESULTS
Schwann Cell Culture Purity and CNPase Expression:
To ensure that the purity of our primary Schwann cell cultures, cells isolated from rat pups (postnatal day 2) were grown on poly-d-lysine coated glass chamber slides and probed for known Schwann cell markers. All the cells in the culture were positive for the Schwann cell markers S100 (Dong et al., 1999 ) ( Figure   1A ) and CNPase (Sprinkle, 1989) ( Figure 1B) . In vivo myelin genes, including CNPase, are upregulated when Schwann cells differentiate. Accordingly, we used a previously characterized "defined" medium to promote differentiation in vitro (Cheng and Mudge, 1996) . In the present study, we validated the method by using western blot to examine the expression levels of CNPase in either Schwann cells cultured only in growth medium verses cells differentiated for 72 hours in defined medium. The levels of CNPase were approximately twice as high in cells differentiated in defined medium than in those cultured only in growth medium ( Figures 1C and   1D ), whereas the expression of non-specific tissue alkaline phosphatase (TNAP) was unchanged. For the metabolism studies, we used the defined medium to promote Schwann cell differentiation. formed 3'-AMP from 2',3'-cAMP at a rate almost a 100-fold less than that of 2'-AMP ( Figure   2B ). As expected there was no formation of either 2'-AMP or 3'-AMP from incubation with any concentration of extracellular 3',5'-cAMP. 3',5'-cAMP was able to form only trace amounts of 5'-AMP; 10-fold less than 3'-AMP and 1000-fold less than 2'-AMP (both from 2',3'-cAMP) ( Figure   2C ). There was no appreciable amount of 5'-AMP from extracellular 2',3'-cAMP. 
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13 releases endogenously produced 2',3'-cAMP. For these experiments, adult rat sciatic nerves were isolated and cut into small sections and incubated for either 0 (basal), 1 or 3 hours. As shown in Figure 6A , when the nerve sections were incubated for 1 and 3 hours in serum free media, the levels of 2',3'-cAMP inside the nerve increased when compared to baseline samples.
In addition, the levels of 2'-AMP increased in the media significantly at 1 and 3 hours ( Figure   6B) ; however, 3'-AMP was not detected in the medium at any time point. Like 2',3'-cAMP, levels of 3',5'-cAMP also increased within the injured nerve at 1 and 3 hours ( Figure 6C ).
However, in contrast to 2'-AMP, levels of 5'-AMP in the medium actually decreased at 1 and 3 hours ( Figure 6D ). Adenosine levels in the nerve did not change over time ( Figure 7A ), whereas adenosine levels in the medium declined at 3 hours ( Figure 7B ). However, adenosine production by peripheral nerves may occur via capsaicin-sensitive sensory afferents (Liu et al., 2002) .
Effects of DPSPX on
Taken together, the results of the present study suggest that peripheral myelinated nerves when subjected to injury generate 2',3'-cAMP which is transported to the extracellular compartment and converted by Schwann cells to 2'-AMP. This mechanism may importantly affect the response of peripheral axons to injury. Recent studies show that 2',3'-cAMP activates mitochondrial permeability transition pores (mPTPs), a process that induces apoptosis and necrosis (Azarashvili et al., 2009) . Therefore, when axons are injured, the metabolism of Of potential pharmacological interest is the observation that Schwann cells appear to have little ability to metabolize any of the AMPs to adenosine. This finding is corroborated by our observations that in injured nerves, extracellular levels of adenosine fall, rather than rise, rapidly with time. Adenosine is an important anti-inflammatory nucleoside that suppresses multiple aspects of both the innate and adaptive arms of the immune system, resulting in the reduced production and release of inflammatory cytokines (Hasko and Cronstein, 2004) . In fact there is a growing body of evidence supporting the concept that regulatory T cells suppress effector T cells mainly via generating adenosine (Mandapathil et al., 2010; Ohta and Sitkovsky, 2014) . The lack of adenosine production by injured peripheral nerves would allow more aggressive immune responses in the vicinity of the injured nerves leading to loss of function and slower recovery. Additionally in the PNS, extracellular adenosine is very much implicated in pain signaling post-nerve injury, with the A 1 receptor being the primary adenosine receptor involved in inhibiting pain transmission (Johansson et al., 2001) . Our findings suggest then that pharmacological approaches to increase adenosine levels in the vicinity of injured peripheral nerves may be useful for preventing subsequent immune-response injury of damaged nerves and to modulate peripheral pain signaling. These hypotheses require further investigation.
It is notable that in Schwann cells, the major metabolite of 2',3'-cAMP is 2'-AMP. It is quite possible that 2'-AMP has pharmacological effects on axons that are completely independent of its metabolism to adenosine. It is tempting to speculate that 2'-AMP (or 3'-AMP) may be an agonist for adenosine receptors as has been shown for 5'-AMP (Rittiner et al., 2012) and that this accumulation of 2'-AMP can activate the A 1 receptor post-injury and thus suppresses nociceptive signaling. However, because little is known regarding the pharmacology of 2'-AMP, at present we cannot speculate as to whether 2'-AMP levels should be augmented our reduced to protect myelinated nerves from injury. Importantly, inhibition of either CD73 or alkaline phosphatase in Schwann cells does not alter the metabolism of 2'-AMP to adenosine, suggesting that these ecto-enzymes, at least in Schwann cells, normally play little role in the metabolism of 2'-AMP. Therefore, pharmacological manipulation of these ecto-enzymes may not alter 2'-AMP levels in Schwann cells.
Inhibition of phosphodiesterase with IBMX inhibits the modest production of 5'-AMP from 3',5'-cAMP, but does not alter the production of 2'-AMP or 3'-AMP from 2',3'-cAMP. Currently there is no selective or potent inhibitor of CNPase. Our novel finding that high concentrations of DPSPX block CNPase provides a starting point for designing more potent and selective inhibitors of this enzyme. Low concentrations DPSPX block adenosine receptors (Daly et al., 1985) , therefore ideally it would be important to synthesize DPSPX analogues that have increased affinity for CNPase yet decreased affinity for adenosine receptors. Such analogues would be invaluable in determining the role of CNPase in physiology and pathology.
Moreover, a potent and selective CNPase inhibitor might have therapeutic benefits. For example, if future studies indicate a detrimental role of 2'-AMP in peripheral nerve injury, a drug similar to DPSPX (but more potent) may be an option to reduce 2'-AMP production in response to peripheral nerve injury. Importantly, our previous studies in rat preglomerular vascular smooth muscle cells and mouse microglia and astrocytes (Verrier et al., 2011) show that DPSPX partially blocks the conversion of 2',3'-cAMP to 2'-AMP (but not 3'-AMP) in those cell types. In light of our new finding that DPSPX partially blocks CNPase activity, these results likely mean that CNPase is involved in forming 2'-AMP in a variety of cell types.
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